Details
Structure visualisation
Entry information
| Complex | |
| AACDB_ID: | 1962 |
| PDBID: | 5XJ4 |
| Chains: | HL_A |
| Organism: | Homo sapiens |
| Method: | XRD |
| Resolution (Å): | 2.30 |
| Reference: | 10.1007/s13238-017-0412-8 |
| Antibody | |
| Antibody: | ipilimumab Fv |
| Antibody mutation: | No |
| INN (Clinical Trial): | Durvalumab(Approved) |
| Antigen | |
| Antigen: | Programmed cell death 1 ligand 1 (PD-L1) |
| Antigen mutation: | No |
| Durg Target: | Q9NZQ7 |
Sequence information
Antibody
Heavy Chain: H
Mutation: NULL
| >5XJ4_H|Chain B[auth H]|durvalumab-VH|Homo sapiens (9606) EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGGWFGELAFDYWGQGTLVTVSS |
Light Chain: L
Mutation: NULL
| >5XJ4_L|Chain C[auth L]|durvalumab-VL|Homo sapiens (9606) EIVLTQSPGTLSLSPGERATLSCRASQRVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSLPWTFGQGTKVEIKRGGGGS |
Antigen
Chain: A
Mutation: NULL
| >5XJ4_A|Chain A|Programmed cell death 1 ligand 1|Homo sapiens (9606) MFTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLAALIVYWEMEDKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGGADYKRITVKVNAPYNKINQRILVVDPVTSEHELTCQAEGYPKAEVIWTSSDHQVLSGKTTTTNSKREEKLFNVTSTLRINTTTNEIFYCTFRRLDPEENHTAELVIPELPLAHPPNER |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
| H: TRP34 ASN51 LYS53 SER57 GLU58 TYR60 ASP63 LYS66 GLU100 TRP103 PHE104 GLY105 GLU106 L: ARG28 SER30 SER31 TYR33 TYR92 GLY93 SER94 LEU95 TRP97 A: MET18 THR20 VAL23 ASP26 TYR56 GLU58 MET59 GLU60 ASP61 VAL111 ARG113 MET115 ALA121 ASP122 TYR123 LYS124 ARG125 ILE126 THR127 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)
